KalVista Pharmaceuticals, Inc.
KALV
$14.66
$1.148.43%
NASDAQ
| 09/30/2025 | 07/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 860.17% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 860.17% | -- | |||
| Cost of Revenue | -16.04% | -0.87% | |||
| Gross Profit | 103.26% | 9.85% | |||
| SG&A Expenses | 4.10% | 14.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.15% | 9.82% | |||
| Operating Income | 21.96% | -7.23% | |||
| Income Before Tax | 18.32% | -9.15% | |||
| Income Tax Expenses | 0.00% | 352.28% | |||
| Earnings from Continuing Operations | 17.66% | -15.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.66% | -15.07% | |||
| EBIT | 21.96% | -7.23% | |||
| EBITDA | 22.12% | -7.28% | |||
| EPS Basic | 18.26% | -14.10% | |||
| Normalized Basic EPS | 18.41% | -8.57% | |||
| EPS Diluted | 18.26% | -14.10% | |||
| Normalized Diluted EPS | 18.41% | -8.57% | |||
| Average Basic Shares Outstanding | 0.72% | 0.85% | |||
| Average Diluted Shares Outstanding | 0.72% | 0.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||